This is a small, recurring sale by a foundation affiliate with no insider (CEO/CFO) involvement. The pattern of identical monthly blocks suggests a 10b5-1 plan or systematic donation-related disposition. No material bearish signal, monitor for any acceleration in selling frequency or a change to open-market sales by officers.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $18.28entry
- T+1 · 3mo ago −0.98%α −0.31% · $18.10
- T+5 · 3mo ago −3.72%α −2.53% · $17.60
- T+20 · 2mo ago −11.60%α −10.07% · $16.16
- T+60 · 7d ago −14.61%α −11.84% · $15.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca Foundation, a major affiliate holder, filed a Form 144 on August 17, 2026, signaling intent to sell 8,333 shares of Erasca, Inc. common stock, with an approximate market value of $152,419 based on the filing date price. The shares were acquired via donation on July 20, 2021, and the seller has also sold identical amounts in June and July 2026, suggesting a pre-arranged or periodic selling plan. The sale is small relative to the $6.4B market cap and the foundation's likely large position, making it a routine liquidity event with minimal directional signal for the stock.
Key Facts
- Erasca Foundation filed Form 144 to sell 8,333 shares of ERAS common stock.
- Estimated sale value ~$152,419 based on filing date.
- Shares were originally acquired via donation on July 20, 2021.
- The foundation sold identical 8,333-share blocks on June 15, 2026 and July 21, 2026, indicating a recurring pattern.
Financial Impact
Proposed sale of 8,333 shares worth ~$152,419, less than 0.01% of Erasca's $6.4B market cap.
Risk Factors
- If the foundation accelerates selling beyond the current 8,333-share monthly pattern, it could signal reduced conviction from a major holder.
- No risk of material dilution given the tiny size relative to market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-057296 |
| Document: 0001628280-26-057296-index.html | 0001628280-26-057296 |
| Document: 0001628280-26-057296.txt | 0001628280-26-057296 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Viewing Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers